Bhupesh Parashar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bhupesh Parashar has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
A. Gabriella Wernicke
Department of Radiation Oncology, Stitch Radiation Center, Weill Cornell Medical Center, New York, NY, 10065, USA
16 shared publicationsDattatreyudu Nori
Department of Radiation Oncology, Weill Cornell Medical Center, New York-Presbyterian Hospital
14 shared publicationsPaul Christos
Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, New York-Presbyterian/Weill Cornell Medical Center
7 shared publicationsAlbert Sabbas
6 shared publications- Prabhsimranjot Singh
Maimonides Medical Center, Brooklyn, NY
5 shared publications Samuel Trichter
Department of Radiation Oncology, Weill Cornell Medical Center, New York
5 shared publications
Latest Publications
- Open Access
- 29 May 2017
- Published by Springer Nature in Cureus
- Vol. 9 (5) , e1284
First Clinical Report on Comparative Treatment and Survival Outcomes in Second Cancers after Primary Head and Neck Cancer: A Population-Based Study
To compare patients’ survival of second primary malignancy (SPM) after head and neck squamous cell carcinoma (HNSCC). The Surveillance, Epidemiology, and End Results (SEER) database was utilized (1973-2011). The Kaplan-Meier method with log-rank test was used to compare the overall survival (OS) and cause-specific survival (CSS) among treatment methods from the time of diagnosis of SPMs. Cox proportional regression models were used to adjust the impact for risk factors on CSS. A total of 3,038 patients were identified (5-yr OS 22.6% (21.0-24.3%)). For head and neck (HN) SPMs, the patients who received ‘conservative surgery with radiation’ had the best 5-yr OS (65.2% (48.9-86.9%)); and the ‘conservative surgery’ group had the best 5-yr CSS (89.9% (85.6-94.5%)). For lung SPMs, the ‘radical surgery’ group showed the best survival (2-yr OS 60.8% (56.0-66.1%), 2-yr CSS 70.6% (65.8-75.8%), respectively). Esophagus SPMs had poor prognosis, with no difference among the treatment groups. In lung SPMs, younger age (p<0.001) and black race (p<0.05) were most favorable CSS predictors. The prognosis of SPMs after HNSCC is worse compared with corresponding primary tumor. Conservative surgery with or without radiation showed the most favorable outcomes in HN SPMs.
- 29 May 2017
- Published by Springer Nature in Cureus
- Vol. 9 (5) , e1284
Open AccessFirst Clinical Report on Comparative Treatment and Survival Outcomes in Second Cancers after Primary Head and Neck Cancer: A Population-Based Study
To compare patients’ survival of second primary malignancy (SPM) after head and neck squamous cell carcinoma (HNSCC). The Surveillance, Epidemiology, and End Results (SEER) database was utilized (1973-2011). The Kaplan-Meier method with log-rank test was used to compare the overall survival (OS) and cause-specific survival (CSS) among treatment methods from the time of diagnosis of SPMs. Cox proportional regression models were used to adjust the impact for risk factors on CSS. A total of 3,038 patients were identified (5-yr OS 22.6% (21.0-24.3%)). For head and neck (HN) SPMs, the patients who received ‘conservative surgery with radiation’ had the best 5-yr OS (65.2% (48.9-86.9%)); and the ‘conservative surgery’ group had the best 5-yr CSS (89.9% (85.6-94.5%)). For lung SPMs, the ‘radical surgery’ group showed the best survival (2-yr OS 60.8% (56.0-66.1%), 2-yr CSS 70.6% (65.8-75.8%), respectively). Esophagus SPMs had poor prognosis, with no difference among the treatment groups. In lung SPMs, younger age (p<0.001) and black race (p<0.05) were most favorable CSS predictors. The prognosis of SPMs after HNSCC is worse compared with corresponding primary tumor. Conservative surgery with or without radiation showed the most favorable outcomes in HN SPMs.
- 28 March 2017
- Published by Springer Nature in Lung
- Vol. 195 (3) , 341-346
Impact of Radiation Therapy in Surgically Resected Limited-Stage Small Cell Lung Carcinoma
To elucidate the role of radiation therapy (RT) in the treatment of surgically resected limited-stage small cell lung carcinoma (LSCLC).
- 28 March 2017
- Published by Springer Nature in Lung
- Vol. 195 (3) , 341-346
Impact of Radiation Therapy in Surgically Resected Limited-Stage Small Cell Lung Carcinoma
To elucidate the role of radiation therapy (RT) in the treatment of surgically resected limited-stage small cell lung carcinoma (LSCLC).
- 22 March 2017
- Published by Springer Nature
- p. 557-582
Lung Brachytherapy
- 14 October 2016
- Published by Wiley in World Journal of Surgery
- Vol. 41 (3) , 758-762
Addition of Surgery After Radiation Significantly Improves Survival in Stage IIIB Non‐small Cell Lung Cancer: A Population‐Based Analysis
Objectives: Limited work, either retrospective or prospective, has been done to investigate whether or not there is a cause‐specific mortality (CSM) or all‐cause mortality (ACM) benefit to adding surgery following neoadjuvant treatment for Stage IIIB NSCLC.Methods: We extracted patients with Stage IIIB NSCLC from the Survival, Epidemiology, and End Results Program (SEER) database treated from 2004 to 2012 with either radiation alone or radiation followed by surgery. Other variables extracted were age, sex, race, and tumor location. The impact of patient and treatment variables on CSM and ACM was explored using Cox multivariable regression analysis.Results: A total of 14,065 patients were extracted from the SEER database. On multivariable analysis, even after adjustment for age, gender, race, and site, radiation followed by surgery was associated with a reduction in cause‐specific mortality compared to radiation alone (adjusted HR 0.46; 95 % CI 0.41, 0.52; p < 0.0001). Median overall survival was 11 months in the radiotherapy alone arm versus 29 months in the radiotherapy plus surgery arm (p < 0.0001 by log‐rank test). After adjustment for these same factors, radiation followed by surgery was also associated with a reduction in all‐cause mortality compared with radiation alone (adjusted HR 0.47; 95 % CI 0.42, 0.52; p < 0.0001). Median cause‐specific survival was 12 months in the radiotherapy alone arm versus 33 months in the radiotherapy plus surgery arm (p < 0.0001 by log‐rank test).Discussion: In the SEER database, there appears to be both a CSM and ACM benefit to adding surgery following radiation for Stage IIIB NSCLC.
- 14 October 2016
- Published by Wiley in World Journal of Surgery
- Vol. 41 (3) , 758-762
Addition of Surgery After Radiation Significantly Improves Survival in Stage IIIB Non‐small Cell Lung Cancer: A Population‐Based Analysis
Objectives: Limited work, either retrospective or prospective, has been done to investigate whether or not there is a cause‐specific mortality (CSM) or all‐cause mortality (ACM) benefit to adding surgery following neoadjuvant treatment for Stage IIIB NSCLC.Methods: We extracted patients with Stage IIIB NSCLC from the Survival, Epidemiology, and End Results Program (SEER) database treated from 2004 to 2012 with either radiation alone or radiation followed by surgery. Other variables extracted were age, sex, race, and tumor location. The impact of patient and treatment variables on CSM and ACM was explored using Cox multivariable regression analysis.Results: A total of 14,065 patients were extracted from the SEER database. On multivariable analysis, even after adjustment for age, gender, race, and site, radiation followed by surgery was associated with a reduction in cause‐specific mortality compared to radiation alone (adjusted HR 0.46; 95 % CI 0.41, 0.52; p < 0.0001). Median overall survival was 11 months in the radiotherapy alone arm versus 29 months in the radiotherapy plus surgery arm (p < 0.0001 by log‐rank test). After adjustment for these same factors, radiation followed by surgery was also associated with a reduction in all‐cause mortality compared with radiation alone (adjusted HR 0.47; 95 % CI 0.42, 0.52; p < 0.0001). Median cause‐specific survival was 12 months in the radiotherapy alone arm versus 33 months in the radiotherapy plus surgery arm (p < 0.0001 by log‐rank test).Discussion: In the SEER database, there appears to be both a CSM and ACM benefit to adding surgery following radiation for Stage IIIB NSCLC.
- 1 February 2016
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 13 (2) , 203-209
Multi-Institutional Implementation and Evaluation of a Curriculum for the Medical Student Clerkship in Radiation Oncology
- 1 February 2016
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 13 (2) , 203-209
Multi-Institutional Implementation and Evaluation of a Curriculum for the Medical Student Clerkship in Radiation Oncology
- Open Access
- 1 January 2016
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 3 (3) , 189-194
Clinical comparison of brachytherapy versus hypofractionated external beam radiation versus standard fractionation external beam radiation for non-melanomatous skin cancers
Purpose : Non-melanomatous skin cancer (NMSC) is the single most common cancer in the US. Radiation therapy is an excellent treatment alternative to surgery. High-dose-rate (HDR) brachytherapy and external beam radiotherapy (EBRT) are commonly used radiation treatment modalities but little data...
- 1 January 2016
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 3 (3) , 189-194
Open AccessClinical comparison of brachytherapy versus hypofractionated external beam radiation versus standard fractionation external beam radiation for non-melanomatous skin cancers
Purpose : Non-melanomatous skin cancer (NMSC) is the single most common cancer in the US. Radiation therapy is an excellent treatment alternative to surgery. High-dose-rate (HDR) brachytherapy and external beam radiotherapy (EBRT) are commonly used radiation treatment modalities but little data...
- 1 September 2015
- Published by Elsevier in Brachytherapy
- Vol. 14 (5) , 648-654
Analysis of stereotactic radiation vs. wedge resection vs. wedge resection plus Cesium-131 brachytherapy in early stage lung cancer
- 1 September 2015
- Published by Elsevier in Brachytherapy
- Vol. 14 (5) , 648-654
Analysis of stereotactic radiation vs. wedge resection vs. wedge resection plus Cesium-131 brachytherapy in early stage lung cancer
- 9 August 2015
- Published by Springer Nature in Current Dermatology Reports
- Vol. 4 (4) , 187-194
Treatment of Non-Melanomatous Skin Cancer with Radiotherapy
- 9 August 2015
- Published by Springer Nature in Current Dermatology Reports
- Vol. 4 (4) , 187-194
Treatment of Non-Melanomatous Skin Cancer with Radiotherapy
- 24 June 2015
- Published by Wiley in The Laryngoscope
- Vol. 125 (9) , 2093-2098
Differences in survival outcome between stage I and stage II glottic cancer: A SEER‐based analysis
Objective: The purpose of this study was to investigate and compare the cause‐specific survival (CSS) of stage I (tumor [T]1 node [N]0 metastasis [M]0) versus stage II (T2N0M0) glottic cancer in a large population cohort.Study Design: We analyzed data from the Surveillance, Epidemiology, and End Results 18 database from 1973 to 2009, comprising patients diagnosed with T1N0M0 or T2N0M0 squamous cell glottic cancer. Kaplan‐Meier survival analysis, multivariable Cox proportional hazards regression analysis, and competing‐risks survival regression were used for statistical analysis.Results: There were 4,422 patients who met all inclusion criteria. The 36‐month CSS was 93.9% for stage I verus 86.5% for stage II, with P < 0.0001. Stage II status conferred a 2.494 hazard ratio for increased risk of cause‐specific death compared to stage I.Conclusions: Stage II glottic cancers have a significantly worse prognosis and may need a different approach to management than stage I tumors.Level of Evidence: 4. Laryngoscope, 125:2093–2098, 2015
- 24 June 2015
- Published by Wiley in The Laryngoscope
- Vol. 125 (9) , 2093-2098
Differences in survival outcome between stage I and stage II glottic cancer: A SEER‐based analysis
Objective: The purpose of this study was to investigate and compare the cause‐specific survival (CSS) of stage I (tumor [T]1 node [N]0 metastasis [M]0) versus stage II (T2N0M0) glottic cancer in a large population cohort.Study Design: We analyzed data from the Surveillance, Epidemiology, and End Results 18 database from 1973 to 2009, comprising patients diagnosed with T1N0M0 or T2N0M0 squamous cell glottic cancer. Kaplan‐Meier survival analysis, multivariable Cox proportional hazards regression analysis, and competing‐risks survival regression were used for statistical analysis.Results: There were 4,422 patients who met all inclusion criteria. The 36‐month CSS was 93.9% for stage I verus 86.5% for stage II, with P < 0.0001. Stage II status conferred a 2.494 hazard ratio for increased risk of cause‐specific death compared to stage I.Conclusions: Stage II glottic cancers have a significantly worse prognosis and may need a different approach to management than stage I tumors.Level of Evidence: 4. Laryngoscope, 125:2093–2098, 2015
- Open Access
- 1 January 2015
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 6 (6) , 445-452
Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes
Purpose : The feasibility and efficacy of re-irradiation using contemporary radiation techniques to treat recurrent head and neck cancer has been demonstrated but the role of brachytherapy is unclear. Here we describe the use of 131 Cs brachytherapy with concurrent salvage surgery in 18...
- 1 January 2015
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 6 (6) , 445-452
Open AccessCesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes
Purpose : The feasibility and efficacy of re-irradiation using contemporary radiation techniques to treat recurrent head and neck cancer has been demonstrated but the role of brachytherapy is unclear. Here we describe the use of 131 Cs brachytherapy with concurrent salvage surgery in 18...